226 related articles for article (PubMed ID: 17222687)
1. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Cartwright R; Cardozo L
J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
[No Abstract] [Full Text] [Related]
2. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
3. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
[No Abstract] [Full Text] [Related]
4. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Fowler CJ
Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
[No Abstract] [Full Text] [Related]
5. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Schurch B
Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
[No Abstract] [Full Text] [Related]
6. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Haferkamp A
Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
[No Abstract] [Full Text] [Related]
7. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
Kuo HC
Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children.
Marte A; Borrelli M; Sabatino MD; Balzo BD; Prezioso M; Pintozzi L; Nino F; Parmeggiani P
Eur J Pediatr Surg; 2010 May; 20(3):153-7. PubMed ID: 20112186
[TBL] [Abstract][Full Text] [Related]
10. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
11. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Lemack GE
Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
[No Abstract] [Full Text] [Related]
12. The case for bladder botulinum toxin application.
Kim DK; Thomas CA; Smith C; Chancellor MB
Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
[TBL] [Abstract][Full Text] [Related]
13. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
[TBL] [Abstract][Full Text] [Related]
14. The current standing of intramural injection of botulinum neurotoxin in managing the overactive bladder.
Drake MJ
BJU Int; 2008 Jul; 102 Suppl 1():1. PubMed ID: 18665970
[No Abstract] [Full Text] [Related]
15. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
16. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
17. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.
Kalsi V; Apostolidis A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ
Eur Urol; 2008 Jul; 54(1):181-7. PubMed ID: 18191323
[TBL] [Abstract][Full Text] [Related]
18. Editorial comment on: Intraprostatic and bladder-neck botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Michel M
Eur Urol; 2008 Mar; 53(3):626-7. PubMed ID: 17950523
[No Abstract] [Full Text] [Related]
19. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
Grosse J; Kramer G; Jakse G
BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
[TBL] [Abstract][Full Text] [Related]
20. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
